Aldeyra Therapeutics Inc. announced new preclinical research results during a recently held research and development webcast. The company revealed that its next-generation RASP modulator, ADX-248, demonstrated promising outcomes in preclinical models of Parkinson's disease and amyotrophic lateral sclerosis. Results showed improvements in grip strength, balance, and central nervous system biomarkers, supporting the potential of ADX-248 as a treatment for neuroinflammatory diseases. The webcast also included updates on the manufacturing of reproxalap, with Aldeyra reporting that recent FDA inspections of its manufacturing facilities were completed with no further action required.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113748228) on November 13, 2025, and is solely responsible for the information contained therein.